Baidu
map

JAMA:西酞普兰可降低因抑郁导致的急性冠状动脉综合征患者长期心血管事件风险

2018-07-25 zhangfan MedSci原创

研究认为,急性冠状动脉综合征后抑郁症患者服用西酞普兰可降低长期主要心血管事件风险

急性冠状动脉综合征(ACS)患者抑郁会导致医疗效果降低。近日研究人员就西酞普兰对ACS抑郁患者长期心血管事件(MACE)的影响进行了考察。

300名合并ACS以及抑郁患者参与研究,随机接受5, 10, 15以及20 mg/d (n=149)的西酞普兰或安慰剂(n=151),持续24周。主要终点为MACE事件,包括全因死亡、心肌梗死(MI)和经皮冠状动脉介入治疗(PCI)。

患者平均年龄60岁,女性占39.3%,全部完成8.1年的随访。西酞普兰组61人(40.9%)以及对照组81人(53.6%)发生MACE事件(HR=0.69),其中西酞普兰组vs对照组,全因死亡风险分别为20.8% vs 24.5%(HR=0.82)、心脏死亡风险为10.7% vs 13.2%(HR=0.79)、MI事件风险为8.7% vs 15.2%(HR=0.54)、PCI风险分别为12.8% vs 19.9% (HR=0.58)。

研究认为,急性冠状动脉综合征后抑郁症患者服用西酞普兰可降低长期主要心血管事件风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (8)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-25 smartxiuxiu

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-25 1ddf0692m34(暂无匿称)

    学习了,长知识

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1706843, encodeId=55dd1e0684358, content=<a href='/topic/show?id=15bd30902cc' target=_blank style='color:#2F92EE;'>#冠状动脉综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=61, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=30902, encryptionId=15bd30902cc, topicName=冠状动脉综合征)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=345831322662, createdName=124985dbm16(暂无昵称), createdTime=Mon Dec 24 18:01:00 CST 2018, time=2018-12-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1643553, encodeId=67a51643553a1, content=<a href='/topic/show?id=6236895092b' target=_blank style='color:#2F92EE;'>#血管事件#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=67, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=89509, encryptionId=6236895092b, topicName=血管事件)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f99523187183, createdName=hukaixun, createdTime=Fri Feb 22 20:01:00 CST 2019, time=2019-02-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1287648, encodeId=785d128e648f9, content=<a href='/topic/show?id=3c3d51e4459' target=_blank style='color:#2F92EE;'>#心血管事件风险#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=60, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=51744, encryptionId=3c3d51e4459, topicName=心血管事件风险)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3138208, createdName=zhanfl, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1431282, encodeId=88ea14312820b, content=<a href='/topic/show?id=f9b9e9124a8' target=_blank style='color:#2F92EE;'>#综合征#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=58, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=79124, encryptionId=f9b9e9124a8, topicName=综合征)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1568389, encodeId=7de41568389fd, content=<a href='/topic/show?id=31e090549c1' target=_blank style='color:#2F92EE;'>#西酞普兰#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=75, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=90549, encryptionId=31e090549c1, topicName=西酞普兰)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=4dcf15370486, createdName=wolongzxh, createdTime=Fri Jul 27 04:01:00 CST 2018, time=2018-07-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334132, encodeId=487633413228, content=好, beContent=null, objectType=article, channel=null, level=null, likeNumber=1, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=18741984753, createdName=smartxiuxiu, createdTime=Wed Jul 25 19:20:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334087, encodeId=7bcf33408e5a, content=学习了,长知识, beContent=null, objectType=article, channel=null, level=null, likeNumber=88, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20220115/46bcf39c32de4aa6b45c5f9d66c8ee77/6cb4a20c55bb4b7691122f47747bfca2.jpg, createdBy=9dad1662329, createdName=1ddf0692m34(暂无匿称), createdTime=Wed Jul 25 14:40:27 CST 2018, time=2018-07-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=334070, encodeId=95303340e0c5, content=了解一下,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=73, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cdnapi.center.medsci.cn/medsci/head/2019/12/23/2f51002e1349ccda5be11c1eea1e1e60.jpg, createdBy=a22097948, createdName=天地飞扬, createdTime=Wed Jul 25 13:39:18 CST 2018, time=2018-07-25, status=1, ipAttribution=)]
    2018-07-25 天地飞扬

    了解一下,谢谢分享!

    0

相关资讯

SECURE-PCI及相关研究解读与启示(一)

急性冠状动脉综合征(Acute Coronary Syndrome,ACS)病情非常凶险,临床上以发作急、病情重和致死率高为特点。规范ACS的诊疗对降低其死亡率和再发生率具有重要的价值。国内外ACS相关指南均强调强化他汀治疗在ACS治疗中的一线地位(IA)。近日,美国心脏病学学会(American College of Cardiology,ACC)年会上发布的SECURE-PCI研究表明,对于A

SECURE-PCI及相关研究解读与启示(二)

急性冠状动脉综合征(Acute Coronary Syndrome,ACS)发病急、病死率高,规范ACS的诊疗对于降低其死亡率和改善预后具有重要价值。国内外ACS相关指南均强调强化他汀治疗在ACS治疗中的一线地位(IA)。近日,美国心脏病学学会(American College of Cardiology,ACC)年会发布的SECURE-PCI研究表明,对于ACS-PCI人群,急性期进行常规强化他

急性冠状动脉综合征特殊人群抗血小板治疗中国专家建议

抗血小板治疗可显著降低冠心病患者的血栓事件风险,国内外指南均将其作为急性冠状动脉综合征(acute coronary syndrome, ACS)治疗的Ⅰ类推荐。但临床实践中,抗血小板治疗的疗效和安全性呈现较大的个体差异,一些血栓和/或出血高风险的特殊患者,在接受常规抗血小板治疗时常发生血栓和出血事件,导致临床决策困难,亟须具体的指导性意见。因此,由中国医师协会心血管内科医师分会血栓防治专业委员会

名家观点系列(三):SECURE-PCI及相关研究解读与启示

急性冠状动脉综合征(Acute Coronary Syndrome,ACS)病情非常凶险,临床上以发作急、病情重和致死率高为特点。规范ACS的诊疗对于降低其死亡率和再发生率具有重要的价值。国内外ACS相关指南均强调强化他汀治疗在ACS治疗中的一线地位(IA)。近日,美国心脏病学会(American College of Cardiology,ACC)年会上发布的SECURE-PCI研究表明,对于A

名家观点系列(四):SECURE-PCI及相关研究解读与启示

急性冠状动脉综合征(Acute Coronary Syndrome,ACS)发病急、病死率高,规范ACS诊疗对于降低死亡率和改善预后具有重要价值。国内外ACS相关指南均强调强化他汀治疗在ACS治疗中的1线地位(IA)。近日,美国心脏病学学会(American College of Cardiology,ACC)年会发布的SECURE-PCI研究表明,对于ACS-PCI人群,急性期进行常规强化他汀治

JAHA:急性冠状动脉综合征的糖尿病患者冠状动脉斑块特征

与非DM患者相比,DM患者在病变和非病变部位具有更多的脆弱特征,从而表现出更高水平的血管不稳定。

Baidu
map
Baidu
map
Baidu
map